The goals of this clinical study are to learn more about the safety and dosing of the study drug, sacituzumab govitecan-hziy, in participants with solid tumors and moderate liver problems.
Advanced or Metastatic Solid Tumor, Liver Failure
The goals of this clinical study are to learn more about the safety and dosing of the study drug, sacituzumab govitecan-hziy, in participants with solid tumors and moderate liver problems.
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
-
Pacific Shores Medical Group, Long Beach, California, United States, 90813
Christiana Care Health Services, Newark, Delaware, United States, 19713
University of Maryland, Baltimore, Maryland, United States, 21201
NEXT Austin, Austin, Texas, United States, 78758
Oncology Consultants, P.A., Houston, Texas, United States, 77030
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States, 77030
NEXT Oncology, San Antonio, Texas, United States, 78229
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Gilead Sciences,
Gilead Study Director, STUDY_DIRECTOR, Gilead Sciences
2026-12